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Peripheral neurotoxicity is the major limiting factor for oxaliplatin therapy. Goshajinkigan (GJG), a traditional Japanese herbal
medicine, was recently shown to be eﬀective in protecting against the neurotoxicity of taxanes in Japan. We retrospectively
investigated the eﬀect of GJG on peripheral neurotoxicity associated with oxaliplatin therapy. Ninety patients with metastatic
colorectal cancer that received FOLFOX4 or modiﬁed FOLFOX6 therapy were assigned to receive one of the following adjuncts:
oral GJG at 7.5g day−1 (Group A, n = 11), intravenous supplementation of calcium gluconate and magnesium sulfate (1g each
before and after FOLFOX) (Group B, n = 14), combined GJG and calcium gluconate and magnesium sulfate therapies (Group
C, n = 2 1 ) ,o rn oc o n c o m i t a n tt h e r a p y( G r o u pD ,n = 44). The incidence of peripheral neurotoxicity was investigated when the
cumulative dose of oxaliplatin exceeded 500mgm−2. When the cumulative dose of oxaliplatin exceeded 500mgm−2, the incidence
ofneuropathy(allgrades)inGroupsA–Dwas50.0%,100%,78.9%,and91.7%,respectively.Itwaslowestinthegroupthatreceived
GJG alone. Concomitant administration of GJG reduced the neurotoxicity of oxaliplatin in patients that received chemotherapy
for colorectal cancer.
1.Introduction
In recent years, the standard chemotherapy for advanced/
recurrent colorectal cancer is a continuous intravenous
infusion of 5-ﬂuorouracil (5-FU) combined with either
oxaliplatin (FOLFOX, FOLFOX4 or modiﬁed FOLFOX6) or
irinotecan (FOLFIRI) [1–3]. Acute and persistent peripheral
neuropathy is the characteristic of oxaliplatin therapy [4],
and the oxaliplatin dose must be limited to avoid toxicity.
Theprevalenceofperipheralneurotoxicity increaseswiththe
total accumulated dose of oxaliplatin, and often interferes
with the continuation of FOLFOX therapy [5]. Gamelin et
al. [6, 7] reported that administration of calcium gluconate
and magnesium sulfate (Ca/Mg) before and after oxaliplatin
therapy could alleviate peripheral neurotoxicity. Other simi-
lartreatmentshavebeendescribed,includingcarbamazepine
[8–10] or glutathione [11], but an eﬀective remedy for
peripheral neurotoxicity related to oxaliplatin therapy has
not yet been established.
Goshajinkigan (GJG) is an extracted traditional Japanese
herbal medicine (Kampo) that is mainly used for the
improvement of symptoms like numbness, cold sensation
and limb pain associated with diabetic neuropathy [12–15].
Moreover, Mamiya et al. [16] and Shindo et al. [17] recently
reported that peripheral neurotoxicity due to oxaliplatin
was relieved by administration of GJG in patients with
advanced colorectal cancer that were receiving FOLFOX
therapy.2 Evidence-Based Complementary and Alternative Medicine
Weconductedthepresentretrospectivestudytocompare
the eﬃcacy of GJG with that of Ca/Mg for alleviation
of peripheral neurotoxicity in patients with advanced or
recurrent colorectal cancer that received either FOLFOX4
therapy or modiﬁed FOLFOX6 (mFOLFOX6) therapy at our
hospital and aﬃliated institutions in Japan.
2. Patientsand Methods
2.1. Patients. This retrospective analysis included 90 patients
with advanced or recurrent colorectal cancer that had
received either FOLFOX4 or mFOLFOX6 therapy from
August2005toJanuary2008atourhospitalandﬁveaﬃliated
institutions. Patients were classiﬁed into the following four
groups: chemotherapy + GJG, chemotherapy + Ca/Mg,
chemotherapy+GJG+Ca/Mgandchemotherapyalone.Full
ethical approval for this study has been obtained from all of
each responsible Ethics Committees in each hospital accord-
ing to Japanese Ministry of Health, Labour and Welfare
guidelines. All patients provided written informed consent.
All records will be kept conﬁdential and the patient’s; name
will not be released at any time.
2.2. Chemotherapy. On Day 1, patients treated with FOL-
FOX4 received a 2-h intravenous infusion of oxali-
platin (85mgm−2) combined with levofolinate (1-LV,
100mgm−2), followed by a bolus injection of 5-FU
(400mgm−2), and then continuous infusion of 5-FU
(600mgm−2) for 22h. On Day 2, 1-LV (100mgm−2)w a s
administered in a 2-h intravenous infusion, and then a
bolus of 5-FU was administered (400mgm−2), followed by a
22-h continuous 5-FU infusion (600mgm−2). This regimen
comprised one course of therapy and was repeated once
every 2 weeks.
On Day 1, patients treated with mFOLFOX6 ther-
apy received a 2-h intravenous infusion of oxaliplatin
(85mgm−2)combinedwith1-LV(100mgm−2),followedby
arapidintravenousinfusionof5-FU(400mgm−2),andthen
a 46-h continuous infusion of 5-FU (2400mgm−2). This
regimen comprised one course of therapy and was repeated
once every 2 weeks.
GJG (7.5mgday
−1 divided into 2-3 doses) was admin-
istered during FOLFOX therapy, given orally before meals
or between meals on a daily basis. Ca and Mg (1g each)
were administered before and after FOLFOX therapy by
intravenous infusion.
2.3. Endpoints and Evaluation. Each group was evaluated
to determine the total dose of oxaliplatin, the median and
mean numbers of courses, the incidence of each grade of
peripheral neuropathy, the incidence of peripheral neuropa-
thy when the total dose of oxaliplatin exceeded 500mgm−2,
the total dose of oxaliplatin at which 50% of patients
showed peripheral neuropathy and the time to treatment
failure (TTF). Peripheral neuropathy evaluations were based
on the Neurotoxicity Criteria of DEBIOPHARM (DEB-
NTC) [18]. The assessment of the occurrence of peripheral
neuropathy in relation to the total dose of oxaliplatin, and
the TTF comparisons were based on Kaplan-Meier analyses.
The attending physicians assessed the anti-tumor eﬀect of
chemotherapy with the new Guidelines for Evaluation of
the Response to Treatment in Solid Tumors (RECIST) [19].
In this retrospective study, Groups A–C were compared
with Group D (no adjunct treatment) with the log-rank
test to identify diﬀerences in the incidence of peripheral
neuropathy and TTF. Diﬀerences observed among groups in
the incidence of peripheral neuropathy at a total oxaliplatin
dose >500mgm−2 and diﬀerences in the anti-tumor activity
were assessed with the chi-square test.
3. Results
3.1. Patient Characteristics. There were an unequal number
of patients in each group (Table 1). Group D (no concomi-
tant therapy) was the largest group and Group A (GJG
alone) was the smallest group. There were no between-group
diﬀerences of sex (P-values are for Groups A (P = .890),
B( P = .223) and C (P = .745) versus Group D by the
χ2-test) and age (P-values are for Groups A (P = .954), B
(P = .470), and C (P = .790) versus Group D by the t-test).
The performance status (PS) was evaluated with The Eastern
Cooperative Oncology Group criteria. A higher percentage
of Group A patients had a PS = 1 compared with the other
groups. None of the patients in Groups A or B had a PS =
2, but there were no signiﬁcant diﬀerences in PS between the
groups (P-values are for Groups A (P = .373), B (P = .316)
a n dC( P = .702) versus Group D by the χ2-test). There were
no diﬀerences in the locations of the primary and metastatic
tumors (P-values are for Groups A (P = .498), B (P = .431)
a n dC( P = .993) versus Group D by the χ2-test).
3.2. FOLFOX Therapy. The chemotherapy regimen most
commonly administered in Group A was mFOLFOX6, and
all of the patients in Groups B and C received mFOLFOX6
therapy. Only Group D had a relatively large number of
patients that received FOLFOX4 therapy. Table 2 shows the
median and mean total doses of oxaliplatin for each group.
Both the median and mean doses were highest in Group
A, followed by Groups C, D and B in descending order.
C o m p a r e dw i t hG r o u pD ,G r o u pBh a das m a l l e rp e r c e n t a g e
of patients (P = .004 by the χ2-test.) that received a total
dose of oxaliplatin exceeding 500mgm−2, but there was no
diﬀerence between the other two groups (P = .466 and .366
by the χ2-test.). Groups A, C and D had similar medians
and mean numbers of courses, but Group B had the lowest
number of courses (Table 2).
3.3. Peripheral Neuropathy. Kaplan-Meier analyses showed
that peripheral neuropathy of Grade 1 or worse (Figure 1)
and Grade 2 or worse (Figure 2) occurred less frequently in
Group A compared with the other groups; the diﬀerence was
most marked for neuropathy of Grade 1 or worse. Peripheral
neuropathy of Grade 3 (Figure 3) did not occur in either
Groups A or C, the two groups that received GJG therapy.
The incidence of peripheral neuropathy at a total oxali-
platin dose >500mgm−2 was lower in the two groups given
GJG(GroupAandGroupC;Table 3).InGroupA,therewere
no cases of Grades 2 or 3 peripheral neuropathy. In GroupEvidence-Based Complementary and Alternative Medicine 3
Table 1: Patient characteristics for the four groups.
Group A
(n = 11)
Group B
(n = 14)
Group C
(n = 21)
Group D
(n = 44)
Total
(n = 90)
Sex
Male 7 6 12 27 52
Female 4 8 9 17 38
Age, median (range) 62 (47–78) 61.5 (54–75) 63 (36–82) 64 (43–87) 63 (36–87)
Body weight, median (range) 59 (41–76) 60 (40–75) 58 (38–77) 59 (39–76) 59 (38–77)
PS
0 7 13 15 38 73
1 4143 1 2
2 00235
Primary tumor
Colon 4 5 10 21 40
Rectum 7 9 11 23 50
Metastasis
Liver 9 9 12 28 58
Lung 3 5 4 18 30
L y m p h n o d e s 02114
O t h e r 2478 2 1
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate; PS, performance status.
Table 2: Details of FOLFOX therapy.
Group A
(n = 11)
Group B
(n = 14)
Group C
(n = 21)
Group D
(n = 44)
Total
(n = 90)
FOLFOX
FOLFOX4 4 0 0 33 37
m F O L F O X 6 7 1 42 11 15 3
Cumulative oxaliplatin Dose
(mgm−2)
Median 807.5 500.0 750.0 680.0 680.0
Mean 726.3 534.3 686.7 625.0 632.3
Range 300–850 170–850 180–850 235–850 170–850
Total oxaliplatin dose
≥500mgm−2 90.9% 42.9% 90.5% 81.8% 78.9%
Percentage of patients (n = 10) (n = 6) (n = 19) (n = 36) (n = 71)
in group
No. of courses
Median 10.0 6.0 10.0 8.0 8.5
Mean 8.9 6.8 8.8 7.9 8.0
Range 4–10 2–10 3–10 3–10 2–10
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
B (Ca/Mg alone), the overall incidence of neuropathy was
comparable to that in Group D (no concomitant therapy),
but Group B had a higher rate of Grade 3 peripheral
neuropathy (Table 3).
The total dose of oxaliplatin at which 50% of the
patients developed peripheral neuropathy was 765mgm−2
in Group A for Grade 1 or worse neuropathy (Table 4).
In Group A, 50% level was not reached for Grade 2 or
worse neuropathy; this suggested that a higher oxaliplatin
dose could be administered to Group A when com-
pared to the other groups before peripheral neurotoxicity
occurred.4 Evidence-Based Complementary and Alternative Medicine
Table 3: Frequency of peripheral neuropathy at a total oxaliplatin dose of 500mgm−2.
Group A, Group B, Group C,
Group D (n = 36) (n = 10) (n = 6) (n = 19)
Percentage P-value Percentage P-value Percentage P-value
All grades 50.0 .002 100 .463 78.9 .178 91.7
Grade 2 0 .130 16.7 .873 5.3 .156 19.4
Grade 3 0 .345 33.3 .080 0 .196 8.3
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
P-values are for Groups A, B and C versus. Group D by the χ2-test.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
n: numbers are patients received over 500mgm−2 dose of total oxaliplatin.
Table 4: Total dose of oxaliplatin at which 50% of patients developed neuropathy.
Group A Group B Group C Group D
(n = 11) (n = 14) (n = 21) (n = 44)
Grade ≥1 765 255 340 255
Grade ≥2 Not reached 510 765 670
Grade 3 — 850 — Not reached
Total oxaliplatin doses are shown in mg/m2.
Grade ≥1, Grade 1 or worse neuropathy; Grade ≥2, Grade 2 or worse neuropathy;
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
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Figure 1: Kaplan-Meier analysis of Grade 1 or worse peripheral
neuropathy in relation to the total dose of oxaliplatin. Group A,
GJG; Group B, calcium gluconate (Ca) and magnesium sulfate
(Mg); Group C, GJG + Ca/Mg; Group D, no therapy. P-values are
for comparison to Group D with the log-rank test.
3.4. Treatment Failure and Discontinuation. The TTF was
∼2 months longer in the groups given GJG than in the
groups without GJG (Figure 4). The rate of discontinuation
of treatment due to tumor progression was 18.2% and 20.5%
in patients that did not receive Ca/Mg (Groups A and D,
resp.), but only 7.1% and 4.8% in those that received Ca/Mg
(Groups B and C, resp.) (Table 5). In Group A, no patients
discontinued therapy due to peripheral neurotoxicity; in
the other groups, the rates ranged from 19.0% to 42.9%.
However, Group A showed a higher discontinuation due to
hematological toxicity than the other groups. There were no
Group A, (P<. 030)
Group B, (P = .032)
Group C, (P = .111)
Group D
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Figure 2: Kaplan-Meier analysis of Grade 2 or worse peripheral
neuropathy in relation to the total dose of oxaliplatin. Group A,
GJG; Group B, calcium gluconate (Ca) and magnesium sulfate
(Mg); Group C, GJG + Ca/Mg; Group D, no therapy. P-values are
for comparison to Group D with the log-rank test.
discontinuations due to patient refusal or change of therapy
inthegroupsadministeredGJG.Also,inGroupA,nearlyhalf
the patients continued the treatment throughout the study
(Table 5).
3.5. Tumor Response. The response rate was 54.5% (6/11) in
Group A, 35.7% (5/14) in Group B, 42.9% (9/21) in Group
C and 45.5% (20/44) in Group D. The disease control rate
(stable disease or better) was 90.9% (10/11) in Group A,
71.4% (10/14) in Group B, 90.5% (19/21) in Group C and
88.6% (39/44) in Group D (Table 6).Evidence-Based Complementary and Alternative Medicine 5
Table 5: Reasons for discontinuation of therapy.
Group A, Group B, Group C, Group D, Total,
Pts (%) Pts (%) Pts (%) Pts (%) Pts (%)
Progressive disease 2 (18.2) 1 (7.1) 1 (4.8) 9 (20.5) 13 (14.4)
Others
Neuropathy 0 6 (42.9) 4 (19.0) 10 (22.7) 20 (22.2)
Myelosuppression 2 (18.2) 1 (7.1) 0 3 (6.8) 6 (6.7)
Allergy 0 0 2 (9.5) 3 (6.8) 5 (5.6)
Other toxicities 1 (9.1) 2 (14.3) 7 (33.3) 9 (20.5) 19 (21.1)
Resection 1 (9.1) 2 (14.3) 3 (14.3) 1 (2.3) 7 (7.8)
Patient refusal 0 1 (7.1) 0 0 1 (1.1)
Change of therapy 0 0 0 5 (11.4) 5 (5.6)
Continuing 5 (45.5) 1 (7.1) 4 (19.0) 4 (9.1) 14 (15.6)
Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
Table 6: Tumor response to treatment (RECIST).
Group A Group B Group C Group D
C R 0000
P R 659 2 0
SD 4 5 10 19
P D 1313
N E 0112
Response Rate 6 (54.5%) 5 (35.7%) 9 (42.9%) 20 (45.5%)
(CR+PR) (P = .589) (P = .522) (P = .844)
Disease Control Rate 10 (90.9%) 10 (71.4%) 19 (90.5%) 39 (88.6%)
(CR+PR+PD) (P = .829) (P = .121) (P = .823)
G r o u pA :G J G ,G r o u pB :C a / M g ,G r o u pC :G J G + C a / M g ,G r o u pD :n ot h e r a p y .
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: no evaluate.
P-values are for Groups A, B, and C versus. Group D by the χ2-test.
GJG: goshajinkigan, Ca: calcium gluconate, Mg: magnesium sulfate.
Group A, (P<. 127)
Group B, (P = .074)
Group C, (P = .052)
Group D
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Figure 3: Kaplan-Meier analysis of Grade 3 peripheral neuropathy
in relation to the total dose of oxaliplatin. Group A, GJG; Group
B, calcium gluconate (Ca) and magnesium sulfate (Mg); Group C,
G J G+C a / M g ;G r o u pD ,n ot h e ra p y .P-values are for comparison to
Group D with the log-rank test.
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by oxaliplatin.
4. Discussion
Peripheral neurotoxicity is a characteristic adverse eﬀect
of oxaliplatin [20]. It is a major obstacle to continuing
treatmentwithregimensthatcontainthisagent;forexample,
FOLFOX. The main symptoms of peripheral neurotoxicity
are typically paresthesia and dysestheia of the extremities
inducedbyexposuretocold.Thesesymptomsoccurin85%–
95% of patients, and the symptom duration becomes longer
with increasing repetitions of chemotherapy courses. It has
been shown that an increase in the total dose of oxaliplatin
leads to the occurrence of pain and sensory dysfunction.
De Gramont et al. [5] reported that functional impairment
occurred in 10% of patients at a total oxaliplatin dose of
850mgm−2, and this increased to 20% at a total dose of
1020mgm−2. Thus, it is important to control peripheral
neurotoxicity in order to allow continued administration of
oxaliplatin. However, control of this side eﬀect is diﬃcult,
because the mechanisms underlying the development of
neuropathy have not been clariﬁed.Evidence-Based Complementary and Alternative Medicine 7
Gamelin et al. [6] suggested that a possible mechanism
may be the eﬀect of oxalate, a metabolite of oxaliplatin,
on neuronal sodium channels. However, based on this
hypothesis, treatment with a sodium channel blocker did
not achieve satisfactory results [20]. This suggested that
sodium channels may only be involved in acute peripheral
neurotoxicity. Neuronal damage has also been attributed to
the accumulation of platinum in the dorsal root ganglion
based on the results from animal experiments [20]. Thus
multiple mechanisms may be involved.
GJG is comprised of 10 herbs and each contains
numerous active ingredients (Figure 5). Thus, in Western
medical terms, GJG is a complex drug, and its overall
pharmacological action is diﬃcult to explain. Until recently,
many Japanese people harbored prejudice toward Kampo
medicine, doubted their eﬃcacy and showed little interest in
their mechanisms [21]. This ignorance of the potential ben-
eﬁts of some herbal medicines is hardly a rare phenomenon,
because skeptics of herbal medicine abound wherever herbal
medications are used, although herbal medicine has been
used throughout the world since time immemorial [22].
Two mechanisms have been suggested by which GJG may
alleviate peripheral neurotoxicity (Figure 5)[ 23–25]. The
ﬁrst is that GJG promotes the release of dynorphin, and thus
improves numbness/pallesthesia via the opiate system. The
second is that GJG promotes nitric oxide production, and
thus improves the circulation and the blood supply to the
nerves.
The present study was a retrospective analysis of periph-
eral neuropathy inhibition in patients that received FOLFOX
therapy combined with GJG, Ca/Mg, GJG + Ca/MG or no
concomitant drug. Although the number of patients was
small, we found that the incidence of peripheral neuropathy
was markedly lower in the groups that received GJG when
compared with those that did not receive GJG; moreover,
there was no Grade 3 peripheral neuropathy in the patients
given GJG. In addition, more courses of chemotherapy could
be given to patients that received GJG than to those not
given GJG; thus, the former also received a higher total dose
of oxaliplatin. Furthermore, the TTF was longer in patients
that received GJG and there were fewer discontinuations due
to peripheral neuropathy than for the other groups. In the
groupofpatientsgivenGJGalone(GroupA),almosthalfthe
patients had continued oxaliplatin therapy throughout the
study, and none discontinued treatment due to peripheral
neurotoxicity. Group A showed a higher discontinuation
due to hematological toxicity than the other groups. As far
as we know, it has never been reported that hematological
toxicity was observed in the patients who used GJG in Japan.
GJG has been safely used for 25 years in Japan for the
improvement of symptoms of numbness, cold sensation and
pain of the extremities associated with diabetic neuropathy
[12–15]. Therefore, hematological toxicity is not likely to
have theadverse eﬀect of GJG. The reason why Group
A showed a higher discontinuation due to hematological
toxicity is probably because Group A patients received
higher dose of total oxaliplatin and 5-FU than other groups.
In addition, that group had higher tumor response rates
and disease control rates than the other groups, indicating
that GJG treatment did not impair anti-tumor activity.
Based on these results, we concluded that concomitant
administration of GJG contributed to the inhibition of
peripheral neurotoxicity and prolonged treatment with
oxaliplatin.
Several authors have previously reported suppression of
peripheral neurotoxicity by Ca/Mg; however, we could not
conﬁrm this eﬀect in this study. In fact, the patients that
received GJG + Ca/Mg developed worse neuropathy than
those that received GJG alone. Accordingly, we suggest that
GJG alone (rather than combined with Ca/Mg) may be
more eﬀective for suppression of peripheral neurotoxicity.
In addition, the tumor response rate was lower in the group
that received GJG + Ca/Mg than in the other groups; this
suggested that some interaction may have occurred when
GJG and Ca/Mg were combined.
A limitation of the present study was that it was a
retrospective review. Also, the number of patients was small,
and some of the baseline characteristics diﬀered between
the groups. Nevertheless, our ﬁndings suggested that the
peripheral neurotoxicity of oxaliplatin could be suppressed
by administration of GJG. It will be necessary to conﬁrm the
usefulness of GJG by performing larger prospective studies
in the future [26].
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